Annual report [Section 13 and 15(d), not S-K Item 405]

Subsequent Events - Checkpoint Merger Agreement (Details)

v3.25.1
Subsequent Events - Checkpoint Merger Agreement (Details) - Subsequent events - Checkpoint Common Stock Warrants - Sun Pharmaceutical Industries, Inc.
$ in Thousands
Mar. 09, 2025
USD ($)
Subsequent Events  
Termination fee payable $ 12,500
Checkpoint Common Stock Warrants  
Subsequent Events  
Cash consideration per each share outstanding 4,100
Maximum contingent consideration per each outstanding share $ 700
Milestone deadline date determination term 36 months
Checkpoint Common Stock Warrants | If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of once every three weeks  
Subsequent Events  
Contingent cash consideration upon achievement of milestone $ 700
Checkpoint Common Stock Warrants | If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of more frequent than once every three weeks  
Subsequent Events  
Contingent cash consideration upon achievement of milestone 450
Checkpoint Common Stock Warrants | If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule once every three weeks  
Subsequent Events  
Contingent cash consideration upon achievement of milestone 450
Checkpoint Common Stock Warrants | If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule more frequent than once every three weeks  
Subsequent Events  
Contingent cash consideration upon achievement of milestone $ 200